Duration of lithium treatment and brain lithium concentration in patients with unipolar and schizoaffective disorder--a study with magnetic resonance spectroscopy

Biol Psychiatry. 1997 Apr 15;41(8):844-50. doi: 10.1016/S0006-3223(96)00330-7.

Abstract

Twenty psychiatric patients on lithium medication were examined with 7-Li-magnetic resonance spectroscopy of the brain. Patients on long-term lithium treatment (> 6 months) were compared with a short-term group who had been taking lithium for between 4 and 8 weeks. Patients met DSM-III-R criteria for either recurrent unipolar depressive disorder (DSM-III-R 296.3x) or schizoaffective disorder, depressive type (DSM-III-R 295.70). The brain:serum lithium ratio was 0.76 +/- 0.26; there was no significant difference between short-term and long-term treatment. In the group of long-term treatment patients there was a positive correlation between lithium dose per day and brain lithium concentration (R = .72, p < .01), and between lithium plasma concentration and brain lithium concentration (R = .65, p < .05). In the short-term group, however, there was no significant correlation for these parameters. No differences between unipolar and schizoaffective disorder were found.

MeSH terms

  • Adult
  • Antimanic Agents / blood
  • Antimanic Agents / pharmacokinetics*
  • Antimanic Agents / therapeutic use*
  • Brain / metabolism*
  • Calibration
  • Depressive Disorder / drug therapy*
  • Depressive Disorder / metabolism*
  • Depressive Disorder / psychology
  • Female
  • Humans
  • Lithium / blood
  • Lithium / pharmacokinetics*
  • Lithium / therapeutic use*
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Psychiatric Status Rating Scales
  • Psychotic Disorders / drug therapy*
  • Psychotic Disorders / metabolism*
  • Psychotic Disorders / psychology
  • Radioisotopes
  • Time Factors

Substances

  • Antimanic Agents
  • Radioisotopes
  • Lithium